Loading...
Loading...
PCSA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 2,714.5K |
| Gross Profit | -2,714.5K |
| Operating Expense | 2,714.5K |
| Operating I/L | -2,714.5K |
| Other Income/Expense | 101.9K |
| Interest Income | 102.0K |
| Pretax | -2,612.6K |
| Income Tax Expense | -20.2K |
| Net Income/Loss | -2,612.6K |
Processa Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing drug products to address unmet medical needs. Its lead product candidate, PCS499, is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica. The company is also developing PCS12852 for gastrointestinal conditions, PCS3117 for pancreatic and lung cancer, and PCS6422 for metastatic colorectal and breast cancer. Additionally, it is working on PCS11T for various cancers. The company generates revenue through the development and potential commercialization of these drug products for patients with chronic and life-threatening conditions.
